Unique binding pocket for KW-4679 in the histamine H1 receptor. 1998

H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo, Sunto, Shizuoka, Japan.

The histamine H1 receptor has an aspartate (Asp) residue in transmembrane helix 3 (TM3), which is well-conserved among biogenic amine receptors. The Asp residue is one of the most crucial amino acids for ligand binding. The tested histamine H1 receptor antagonists with tri- and tetracyclic structures were not selective for histamine H1 receptors and showed affinity for several other biogenic amine receptors. In contrast, KW-4679 ((Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b, e]oxepin-2-acetic acid hydrochloride), a tricyclic compound, was a selective histamine H1 receptor antagonist. [3H]KW-4679 had high affinity (Kd value of 2.5 +/- 0.12 nM) for wild-type human histamine H1 receptors. In the [3H]KW-4679 binding assay, replacement of Asp107 by alanine by site-directed mutagenesis greatly reduced the affinities (280-2100-fold) of tri- and tetracyclic compounds, whereas this mutation led to a comparatively small reduction (14-fold) in KW-4679 affinity. These results demonstrate that the tested tri- and tetracyclic histamine H1 receptor antagonists which have a tight interaction with the Asp residue are not selective for the histamine H1 receptor. Furthermore, the high selectivity of KW-4679 might be explained by a unique binding pocket, which consists of the Asp residue and other acceptor sites, in the histamine H1 receptor.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011969 Receptors, Histamine H1 A class of histamine receptors discriminated by their pharmacology and mode of action. Most histamine H1 receptors operate through the inositol phosphate/diacylglycerol second messenger system. Among the many responses mediated by these receptors are smooth muscle contraction, increased vascular permeability, hormone release, and cerebral glyconeogenesis. (From Biochem Soc Trans 1992 Feb;20(1):122-5) H1 Receptor,Histamine H1 Receptors,H1 Receptors,Histamine H1 Receptor,Receptors, H1,H1 Receptor, Histamine,H1 Receptors, Histamine,Receptor, H1,Receptor, Histamine H1
D003990 Dibenzoxepins
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069605 Olopatadine Hydrochloride An antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of ALLERGIC CONJUNCTIVITIS. 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid,KW 4679,KW-4679,KW-4943A,Olopatadine,Patanol,4679, KW,Hydrochloride, Olopatadine,KW 4943A,KW4943A
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
March 2004, European journal of pharmacology,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
January 2007, Journal of the American Chemical Society,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
April 2005, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
August 1990, Journal of neurochemistry,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
July 2005, Nature chemical biology,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
January 1993, General pharmacology,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
February 1994, The Journal of pharmacology and experimental therapeutics,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
April 2005, Molecular pharmacology,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
August 1990, Neuroscience letters,
H Nonaka, and S Otaki, and E Ohshima, and M Kono, and H Kase, and K Ohta, and H Fukui, and M Ichimura
August 2004, The European journal of neuroscience,
Copied contents to your clipboard!